Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Nanjing Tianyinshan Hospital acts as a sponsor and major clinical site in early and exploratory clinical trials of innovative immunotherapies (including mRNA vaccines and monoclonal antibodies) for advanced cancers and is actively enrolling patients in multiple Phase 1 and exploratory studies[1].
- Therapeutic areas
- Oncology
- Modalities
- Therapeutic vaccinemRNA vaccineMonoclonal antibody
- Industry
- Academic Hospital/University/Research
02
Partnerships
Shanghai Shengdi PharmaceuticalJiangsu Hengrui PharmaceuticalsShanghai Regenelead Therapies
Beyond the preview
Go deeper on Nanjing Tianyinshan Hospital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Tianyinshan Hospital.